COVID-19 and APOE4: Severity Risk and the Brain, What's Actually Established

Early in the pandemic, UK Biobank data showed that people with two copies of APOE4 who caught COVID-19 were more than four times as likely to die from it as people with the common E3/3 genotype. That is an alarming headline, and it is real, but it rests on 13 deaths among 59 infected two-copy carriers, which is a small enough number to make the estimate jumpy. Separately, lab work hints the E4 protein may make brain cells easier for the virus to infect. Here is what is actually established for carriers, and the much larger pile of what is not.

What the evidence actually shows

The severity signal comes from a 2020 study by Chia-Ling Kuo and colleagues using the UK Biobank. Among people who tested positive for COVID-19, those with the E4/4 genotype had about a 4.3-fold higher odds of dying (odds ratio 4.29, 95% confidence interval 2.38 to 7.72) compared with E3/3, and a roughly 2.2-fold higher odds of testing positive at all (OR 2.24, CI 1.72 to 2.93). The effect looked recessive, meaning it showed up mainly in people with two copies, not one.

Translate the relative number into absolute terms, because that is where it becomes honest. Among 59 infected E4/4 carriers, 13 died, a case fatality of roughly 22% in this older cohort. Among 663 infected E3/3 people, 79 died, about 12%. So the absolute gap in this early sample was real but built on small counts, especially the 13 deaths driving the E4/4 estimate. That is exactly why the confidence interval is wide (a true effect anywhere from about 2.4 to 7.7 times). Wide intervals are the statistics telling you to hold the number loosely. This was also early-pandemic data, before vaccines, before good treatment, in a sample skewed older, so it does not necessarily describe risk today.

Then there is the brain question, which has two separate strands that often get blurred into one overstated claim.

The first strand is laboratory cell work. In a 2021 Cell Stem Cell study, researchers made genetically matched ApoE3/3 and ApoE4/4 human stem-cell-derived brain cells and exposed them to SARS-CoV-2. The E4/4 neurons and astrocytes were infected at a higher rate than E3/3, and infected E4 astrocytes looked sicker (enlarged, with more fragmented nuclei). That is a clean, suggestive result about a possible vulnerability. It is also cells in a dish, not a person, and a higher infection rate in cultured cells does not establish that carriers suffer more brain damage from COVID.

The second strand is human brain imaging. A 2022 Nature study (Douaud and colleagues, also UK Biobank) scanned people before and after infection and found measurable changes after even mild COVID: greater loss of grey matter and tissue contrast in regions tied to smell and memory, plus a small drop on a cognitive test. It is the strongest evidence that COVID can leave a mark on the brain. But here is the part that matters for this page: that study did not analyze APOE genotype. It tells us nothing about whether carriers are hit harder. Anyone claiming it shows an APOE4 brain effect is reading something into it that is not there.

So the brain-specific question for carriers, does COVID damage an APOE4 brain more than anyone else’s, is essentially untested in humans. We have a lab hint and an unrelated human imaging finding, and no study that connects them.

Why APOE might matter for a virus

ApoE is best known for moving cholesterol and fats around the body and brain, but it sits at a busy intersection: it shapes inflammation, helps maintain the blood-brain barrier, and interacts with the immune response. A respiratory virus that drives severe disease through runaway inflammation and blood-vessel damage is operating on the same machinery ApoE helps run.

Think of ApoE as the building manager for the brain and blood vessels: it keeps the locks maintained, the inflammation thermostat in range, and the barrier walls patched. The E4 version does that maintenance less well. The plausible idea is simply that a sloppier building manager leaves a few more doors unlocked for an opportunistic intruder, whether that means easier cell entry (the dish data) or a more damaging inflammatory response (the severity data). It is a coherent mechanism. It is not proof, and it does not tell you the size of any real-world effect.

The numbers in one place

What	Figure	Context
Death risk, E4/4 vs E3/3 (infected)	OR 4.29 (CI 2.38-7.72)	Relative; early-pandemic, recessive pattern
Absolute fatality, infected E4/4	~22% (13 of 59)	Older cohort, small counts
Absolute fatality, infected E3/3	~12% (79 of 663)	Same cohort, for comparison
Test-positive risk, E4/4 vs E3/3	OR 2.24 (CI 1.72-2.93)	Relative
Brain cell infection (E4 vs E3)	Higher in E4 neurons/astrocytes	Cell models, not people
Human brain imaging by APOE	Not examined	The 2022 Nature study did not analyze genotype

The honest caveats

The severity signal is the most solid piece here, and even it needs hedging. It is observational, from one cohort, early in the pandemic, before vaccines and modern treatment, and driven by a handful of deaths in the two-copy group. That combination (small subgroups, wide intervals, a since-changed treatment landscape) is exactly the setup where an early number can shrink or shift as more data arrive. Treat “four times” as a flag worth knowing, not a fixed personal multiplier for today.

The brain side is weaker still. Lab susceptibility in cultured cells is a hint about mechanism, not a clinical outcome. The human imaging evidence that COVID can affect the brain is real but says nothing about APOE, because genotype was never in that analysis. So the specific worry many carriers have, that COVID is uniquely bad for an E4 brain, is currently unproven in either direction. Unproven means do not panic and do not dismiss; it means the study has not been done.

What this means for you

There is no APOE4-specific COVID guidance, and you should be skeptical of anyone who offers it, because the evidence does not support a carrier-only protocol. The sensible move is the boring one: follow standard prevention and vaccination advice appropriate to your age and health, the same advice that applies to everyone in your risk band. Vaccination, sensible precautions during surges, and prompt treatment if you are higher-risk are well-supported tools that work regardless of genotype.

What being a carrier reasonably adds is a slightly lower threshold for taking COVID seriously rather than shrugging it off, given the early severity signal and your existing interest in protecting your brain. That is a mindset, not a separate medicine. To understand why your genotype touches so many systems (and why that makes a multi-system virus worth respecting), see how APOE4 affects the brain. And to keep early, wide-confidence-interval findings like the severity number in proportion rather than letting one alarming headline run your decisions, reading a study like a skeptic is the right companion piece. The honest summary is short: take normal precautions, do not over-read an early signal, and do not wait for an APOE4-specific COVID study to look after your health today.

Common questions

Does having APOE4 mean COVID will be much worse for me? The early data showed higher severity in two-copy carriers, but that estimate came from small numbers before vaccines and good treatment, and it does not cleanly translate to your risk now. One copy showed little effect. Take it as a reason to use standard precautions, not as a fixed personal odds.

Does COVID damage an APOE4 brain more than other people’s? That has not been tested in humans. Lab cells with the E4 genotype were easier to infect, and COVID can affect the brain in general, but no study has linked those two to show carriers are hit harder.

Should I do anything different from non-carriers? No special protocol exists. Follow the vaccination and prevention advice for your age and health. The most you might reasonably do is take the virus a notch more seriously rather than less.

Is the four-fold death risk still accurate? Probably not as a current figure. It reflects an early-pandemic, older, unvaccinated sample and rests on 13 deaths. The treatment and vaccine landscape has changed enormously since.

Know the early signal, respect the virus, and use the standard, well-tested tools. The carrier-specific story is mostly still unwritten, so do not let one wide-interval number drive your choices. This is general education, not medical advice.

Sources

• Kuo CL, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci, 2020. Journal article
• Wang C, et al. ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response. Cell Stem Cell, 2021. PubMed 33450186
• Douaud G, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature, 2022 (did not examine APOE genotype). Nature article